UNSPSC 51384523: Flurbiprofen axetil

This classification denotes a cyclooxygenase inhibitor and carbonic anhydrase inhibitor C19H19FO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I0OU31PUI5, chemically known as (1,1'-biphenyl)-4-acetic acid, 2-fluoro-.alpha.-methyl-, 1-(acetyloxy)ethyl ester, but more generally known as flurbiprofen axetil, which bears US NIH Compound Identifier 3395. European Medicines Agency schedules Flurbiprofen axetil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02239MIG.

Most nations, for tariff and trade purposes, schedule flurbiprofen axetil under HS 29163900 and SITC 51379. As of Q4 2014, FLURBIPROFEN AXETIL remains US FDA's Preferred Term for this commodity. SMILES: CC(C1CCC(C(C1)F)C2CCCCC2)C(=O)OC(C)OC(=O)C.

UNSPSC 51384523 Flurbiprofen axetil is a Commodity code that sits at the intersection of pharmaceutical procurement and state and local health-system purchasing, though recent solicitation activity tagged to this code shows substantial mismatch between the nominal product scope and actual buying patterns. State and local governments soliciting under this code are acquiring naloxone kits, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through competitive bidding and cooperative purchasing vehicles, not flurbiprofen axetil specifically. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, covering Minnesota, Oregon, and member states). The mix spans health departments, pharmacy benefit programs, and direct-to-manufacturer prescription initiatives; no single jurisdiction emerges as a repeat buyer in recent activity.

Recent procurement activity centers in Florida, Texas, and Minnesota. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a due date of July 26, 2023 (note: date appears inconsistent with posting date); the contract includes a two-year initial term with optional one-year renewal and requires E-Verify compliance and multiple insurance coverages. The Texas HHS Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity and negotiated pricing models. MMCAP, administered by the Minnesota Department of Administration, posted RFP S1070000015802 in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson; proposals were due March 26, 2026, with contract awards effective July 1, 2026, and evaluations weighting price competitiveness at 75 percent. The code shows active state and local procurement in pharmaceutical supply and harm-reduction products, though the mismatch with the nominal flurbiprofen axetil scope suggests potential tagging inconsistency in the source data.